16/04/2026
✨ Meet Lipotris™. Our new, unique product is designed to support patients affected by osteoarthritis (OA).
🔬 Developed by Biovico and distributed by its sister company in Wilandt Brothers HLDG – Implai solution combines hyaluronic acid with synthetic liposomes to interact with lubricin on the cartilage surface.
This synergy is designed to create an ultra-low-friction layer, supporting smoother joint motion and potentially faster symptom relief with a sustained clinical effect.*
🧬 Administered as a course of intra-articular injections, Lipotris™ supports joints and helps maintain function in patients with osteoarthritis. It is confirmed by clinical studies* and the patent obtained by Biovico.
Last week Lipotris™ has officially entered the market. Implai will act as its Global Distributor to reach the network of new and existing partners all around the world.
We’re truly excited to see another solution reach patients and offer real support on their path to recovery.
* Bakowski, P., & Madej, W. (2024). Liposomal intra-articular gel provides components for ultra-low friction in the synovial joint, thus improving clinical and functional outcomes of patients with osteoarthritis. Osteoarthritis and Cartilage, 32, S45-S46.
